Erratum to: Cost Effectiveness of Apixaban Versus Aspirin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in Belgium

被引：0
|
作者：
Thitima Kongnakorn
Tereza Lanitis
Lieven Annemans
Vincent Thijs
Sophie Marbaix
机构：
[1] Evidera,Laboratory of Neurobiology
[2] Evidera,Experimental Neurology and Leuven Research Institute for Neurodegenerative Diseases (LIND)
[3] Ghent University (Ugent),Department of Neurology
[4] Brussels University (VUB),undefined
[5] Vesalius Research Center,undefined
[6] VIB,undefined
[7] University of Leuven (KU Leuven),undefined
[8] University Hospital Leuven,undefined
[9] Pfizer,undefined
来源：
Clinical Drug Investigation | 2014年 / 34卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：753 / 753
相关论文
共 50 条
  • [21] Cost-effectiveness of Apixaban versus Warfarin and Aspirin in Sweden for Stroke Prevention in Patients with Atrial Fibrillation
    Lanitis, Tereza
    Kongnakorn, Thitima
    Jacobson, Lena
    De Geer, Anna
    THROMBOSIS RESEARCH, 2014, 134 (02) : 278 - 287
  • [22] Cost analysis: apixaban versus other anticoagulation in patients with non-valvular atrial fibrillation
    Kunde, Katharina
    GESUNDHEITSOEKONOMIE UND QUALITAETSMANAGEMENT, 2022, 27 (06): : 282 - 283
  • [23] Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective
    Kostas Athanasakis
    Nadia Boubouchairopoulou
    Eleftheria Karampli
    Filippos Tarantilis
    Paraskevi Savvari
    Aikaterini Bilitou
    John Kyriopoulos
    American Journal of Cardiovascular Drugs, 2017, 17 : 123 - 133
  • [24] Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis
    Rognoni, Carla
    Marchetti, Monia
    Quaglini, Silvana
    Liberato, Nicola Lucio
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2015, 39 (02) : 149 - 154
  • [25] Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis
    Carla Rognoni
    Monia Marchetti
    Silvana Quaglini
    Nicola Lucio Liberato
    Journal of Thrombosis and Thrombolysis, 2015, 39 : 149 - 154
  • [26] COST-EFFECTIVENESS OF APIXABAN COMPARED TO WARFARIN AND ASPIRIN IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION (NVAF) IN THE RUSSIAN FEDERATION
    Rudakova, A., V
    Parfenov, V. A.
    VALUE IN HEALTH, 2014, 17 (07) : A489 - A489
  • [27] PHARMACOECONOMIC ASSESSMENT OF APIXABAN VERSUS STANDARD OF CARE FOR THE PREVENTION OF STROKE IN ITALIAN NON-VALVULAR ATRIAL FIBRILLATION PATIENTS
    Pradelli, L.
    Calandriello, M.
    Di Virgilio, R.
    Bellone, M.
    Tubaro, M.
    VALUE IN HEALTH, 2014, 17 (07) : A486 - A487
  • [28] Economic Evaluation of Apixaban for the Prevention of Stroke in Non-Valvular Atrial Fibrillation in the Netherlands
    Stevanovic, Jelena
    Pompen, Marjolein
    Le, Hoa H.
    Rozenbaum, Mark H.
    Tieleman, Robert G.
    Postma, Maarten J.
    PLOS ONE, 2014, 9 (08):
  • [29] ESTIMATION OF THE COST-EFFECTIVENESS OF APIXABAN IN NON-VALVULAR ATRIAL FIBRILLATION IN ARGENTINA
    Giorgi, M. A.
    Caroli, C.
    Micone, P.
    Giglio, N. D.
    Aiello, E. C.
    Donato, B. M. K.
    Mould, J. F.
    Radero, G.
    Casas, M.
    VALUE IN HEALTH, 2013, 16 (07) : A666 - A666
  • [30] Cost-effectiveness of Dabigatran for Stroke Prevention in Non-valvular Atrial Fibrillation in Spain
    Gonzalez-Juanatey, Jose R.
    Alvarez-Sabin, Jose
    Lobos, Jose M.
    Martinez-Rubio, Antoni
    Reverter, Joan C.
    Oyagueez, Itziar
    Gonzalez-Rojas, Nuria
    Becerra, Virginia
    REVISTA ESPANOLA DE CARDIOLOGIA, 2012, 65 (10): : 901 - 910
12345